{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-24-000088","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.155733+00:00","generated_at":"2026-05-30T04:37:58.209140+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Keros Q3 net loss $53M; cash $530.7M; Phase 2 PAH trial fully enrolled","bullets":["Net loss of $53.0M in Q3 2024 vs $39.4M in Q3 2023; R&D expenses rose to $49.2M.","Cash and cash equivalents $530.7M as of Sep 30, 2024; ATM proceeds extend runway into Q3 2027.","Completed enrollment ahead of schedule in Phase 2 TROPOS trial (cibotercept) for pulmonary arterial hypertension.","Appointed Yung H. Chyung, M.D. as Chief Medical Officer effective Nov 1, 2024.","Expects clinical data updates from three assets over next nine months."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-24-000088","json":"https://secwatch.observer/filing/0001664710-24-000088.json","markdown":"https://secwatch.observer/filing/0001664710-24-000088.md","text":"https://secwatch.observer/filing/0001664710-24-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000088/0001664710-24-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000088/kros-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:37:58.209140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}